Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis.

Kirsten DanielsP B van der NatS T F M FrequinP J van der WeesD H BiesmaE L J HoogervorstE M W van de Garde

Published in: Multiple sclerosis international (2020)

Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

Keyphrases

multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
white matter
patient reported